Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLC

Margarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.

Margarita Majem, MD, PhD, a faculty member in the Department of Medical Oncology at the Hospital de la Santa Creu i Sant Pau, discusses the safety profile of osimertinib (Tagrisso) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Osimertinib continues to showcase a favorable safety profile, similar to what has been observed in previous studies such as the ADAURA (NCT02511106) or FLAURA (NCT02296125) trials, Majem says. Moreover, the safety profile of the third-generation TKI appears to better than what has been observed with first- and second-generation TKIs, Majem notes.

It’s important that this therapy is tolerable, as patients will receive treatment for up to 3 years. Thus far, osimertinib appears to be a beneficial option for this patient population, as it allows for extended treatment without dose interruption or reduction due to toxicity, Majem concludes.